Sobi - North America的动态

Taken from Chapter 6: Syphilis is a disease with a long and terrible history. Since it was first described around 1500 AD, syphilis has remained a mystery in many ways. Legend has it that syphilis first came to be when... to read more, go to page 83. https://lnkd.in/g5WmJwzz #flesheatingbacteria #booktok #bookstagram

In our latest video on VuMedi, we discuss the key findings from the recent Clinical Infectious Diseases article, "Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response." A big thanks to VuMedi for providing this platform to share valuable insights with the infectious disease community. ?? Watch the full video to learn more. https://lnkd.in/gx4HvHkC

??Today, we are proud to launch Unite4Rare, Sobi’s long-standing commitment to the rare disease community. At Sobi - Swedish Orphan Biovitrum AB (publ),?meaningful patient engagement in rare diseases is built into our company DNA.?? ??Co-created with internationally renowned patient leaders, this initiative outlines what individuals, and their families can expect from us through four dedicated pillars: Connect, Nurture, Collaborate and Innovate – each supported by measurable commitments. ??The launch of Unite4Rare marks an important milestone in our journey to transform the lives of people living with rare and debilitating diseases.?? Learn more about Unite4Rare and what it means to Sobi: https://lnkd.in/dbkhfKYZ.

News from #NACFC2024: We are presenting new data on our cystic fibrosis medicines at the 2024 North American Cystic Fibrosis Conference. Learn more: https://lnkd.in/enYuwYy7

Have you found yourself suddenly allergic to foods and chemicals that didn't bother you before? This may be due to mast cell activation syndrome--when your immune system goes haywire. MCAS may be experienced by people with Lyme disease and/or mold toxicity and can even be life-threatening. This special issue of the Lyme Times takes a deep dive into MCAS--and what it takes to heal from this troubling condition. It includes articles written by MCAS experts, including Tania Dempsey, MD, ABIHM; Todd Maderis, N.D.; Jill C. Carnahan, MD; and Beth O'Hara, FN. There's also a review and excerpt of Dr. Neil Nathan's important new book "The Sensitive Patient's Healing Guide." And more. Click here to read now. https://lnkd.in/gf89Ac3S

Excellent topic. Diagnostic stewardship is as important as antibiotic stewardship.

Secure your spot in this very important scientific activity .

Dear All, We are pleased to invite you to the upcoming Journal Club session scheduled for this Thursday, September 12th, at 3 pm UK time. During this session, our focus will center on the captivating topic of the paper "Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann–Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn’s disease" by Schwerd et al., published in BMJ Journals (2016) (DOI: https://lnkd.in/d4hZgbMX) Our colleagues, Beatrice Budeanu and Vlad Buic?, will present a study that discusses a critical connection between impaired antibacterial autophagy and the development of granulomatous intestinal inflammation, as observed in Niemann–Pick disease type C1 (NPC1) and XIAP deficiency, and how this relates to NOD2 variants associated with Crohn’s disease. We look forward to the active participation of as many of you as possible this Thursday. You can join the session via the following link: https://lnkd.in/dHaVbgZe Warm regards from the JC team: Elena-Raluca Nicoli Pharm., Ph.D., M.B.A. Vlad Buica Adela-Daria Neac?u Lindsay Russell Mihai-Stefan Catanescu Beatrice Budeanu Teamwork makes the dream work! P.S. Ensure to use a time converter such as https://lnkd.in/gQYQByZ (https://lnkd.in/gQYQByZ) to accurately determine your time zone.

?? "BREAKTHROUGH: HOPE NOW FOR RARE KIDNEY DISEASE." Fellow patients and nephrologists, don't miss Dr. Anna Greka's presentation at 1:30 p.m. EST on Tuesday. A promising compound that may HALT rare kidney diseases is being finalized for a Clinical Trial -- yet we need your help to find 300 hundred more patients. MUC1 and UMOD (ADTKD) have gone from ultra-rare diseases nine years ago to 75,000 to 100,000 undiagnosed patients in the US. Sadly, patients and physicians are not aware of why these kidneys are failing. It's estimated that 25% of patients on dialysis don't know why either. Please contact us at RAREKIDNEY.ORG to see if you qualify for a free genetic test or one your physician can prescribe for you now. Physicians, you're invited to join the new RARE KIDNEY CLINICAL COUNCIL-- first, to help diagnose all your patients. See additional reasons why you should join at rarekidney.org. Sincere thanks, Rich Nelson Kidney transplant patient - 33 years. [email protected] PLEASE FOLLOW - AND SHARE THIS URGENT MESSAGE. #muchhopetoHALTkidneydisease #rarekidneydisease #HALTrarekidneydisease #rarekidneyHOPE #HALTMUC1 #HALTUMOD #HALTADTKD

Antimicrobial resistance (AMR) is invisible, but patients are not. Is just on 18/11 the European Antibiotic Awareness Day 2024. A digital event aimed at raising awareness of the impact of antimicrobial resistance (AMR) on people’s lives, keeping the patients at the centre of the discussion. https://lnkd.in/d3rrNfUa